These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 14663007)

  • 21. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
    Kanda T; Uchida S
    Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
    Grondin R; Bédard PJ; Hadj Tahar A; Grégoire L; Mori A; Kase H
    Neurology; 1999 May; 52(8):1673-7. PubMed ID: 10331698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments.
    Jenner P
    J Neurol; 2000 Apr; 247 Suppl 2():II43-50. PubMed ID: 10991665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-parkinsonian activity of the adenosine A
    Ohno Y; Okita E; Kawai-Uchida M; Fukuda N; Shoukei Y; Soshiroda K; Yamada K; Kanda T; Uchida S
    Eur J Pharmacol; 2023 Jul; 950():175773. PubMed ID: 37146707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR; Pinna A; Tronci E; Morelli M
    Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
    Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
    Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
    Jenner P
    Neurology; 2003 Sep; 61(6 Suppl 3):S4-11. PubMed ID: 14504374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
    Hodgson RA; Bedard PJ; Varty GB; Kazdoba TM; Di Paolo T; Grzelak ME; Pond AJ; Hadjtahar A; Belanger N; Gregoire L; Dare A; Neustadt BR; Stamford AW; Hunter JC
    Exp Neurol; 2010 Oct; 225(2):384-90. PubMed ID: 20655910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
    Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
    Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
    Jenner P
    Neurology; 2002 Feb; 58(4 Suppl 1):S1-8. PubMed ID: 11909980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
    Müller T
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.